NOTES: Viking / Hims & Hers: The Great GLP-1 Vending Machine Scam
The compounded GLP-1 hustle is over. As Hims & Hers pivots to branded Wegovy, patients face severe price hikes while competitors like Amazon and Eli Lilly undercut the market. Welcome to the biological ransom.
Listen on
Listen (episode)SpotifyApple PodcastsRSS
The Cassandra Files — forensic audio drama. Katie audits the books, Marcus kills the spin, Killian opens the file. About · Latest · Themes
San Francisco is choking on fog today, 68 degrees and thick with distant ambulance sirens. It reminds me of a neon-soaked bender in Shinjuku back in 2018—where the promises were cheap, the hype was blinding, and the hangovers were ruthlessly expensive.
That is exactly what is happening to Hims & Hers right now. The boys in the boardroom built a vending machine for metabolic hope, but mate, the coins keep jamming.
If you listen to the official spin from CEO Andrew Dudum, HIMS is the "OS for personalized healthcare." It is classic Silicon Valley cactus tech. They boast about a "4.1x LTV:CAC flywheel" and an AI-driven platform democratizing access to the diabesity ecosystem.
Here is the fleecing.
The entire compounded GLP-1 model was a temporary regulatory arbitrage play. The music stopped abruptly in February 2026 when the FDA terminated the semaglutide shortage. Now? It is a brutal bait-and-switch. Desperate patients who signed up for $49-a-month compounded shots are getting slammed with $1,000-plus bills for branded Wegovy. That is the true human cost of this cultural rot.
The pivot to physical GLP-1 distribution is bleeding them dry. Gross margins collapsed from 82% in 2023 down to 74% in 2025. Q1 2026 delivered a staggering $92.1 million net loss and $33 million in restructuring charges. Subscriber growth is crawling at just 9%—the slowest expansion rate since 2021. Revenue guidance? Slashed from a hyped $6.5 billion dream down to $3 billion.
They are not an AI platform. 90% of their revenue is just repackaged pharmacy fulfillment.
And the apex predators are circling. Eli Lilly’s direct-to-consumer platform is undercutting them by 20%. Amazon is dropping same-day GLP-1s via Prime. Ro is underbidding them on mental health by 15%. Even the pharmaceutical side is stalling; Viking Therapeutics delayed its Phase 3 oral trial to Q4, all while pushing "maintenance dosing"—a sanitized jargon term for lifelong biological dependency.
HIMS stock is down 46% from its peak for a reason. CFO Yemi Okupe can raise $350 million in debt to restructure the mess, but you cannot outrun a DOJ referral or the laws of physics. They aren't curing the metabolic crisis. They are just renting patients their own metabolisms until the cash runs out.
